COR Cencora
FY2025 10-K
Cencora (COR) filed its fiscal year 2025 10-K annual report with the SEC on Nov 25, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Pharmaceutical distribution competing with manufacturers, chain drugstores, specialty distributors, packaging, and healthcare technology firms
- • Emphasized regulatory compliance due to new U.S. and EU laws (DSCSA, Falsified Medicines Directive, EU Critical Medicines Act, EU HTA Regulation effective Jan 2025)
Management Discussion & Analysis
- • Revenue $321.3B, up 9.3% YoY; U.S. Healthcare Solutions revenue $291.0B, up 9.7% ($25.6B increase); International Solutions $30.4B, up 6.1% ($1.7B increase)
- • Operating margin total 0.82% approx. (operating income $2.63B / revenue $321.3B); U.S. Healthcare margin 1.23%, up 12 bps YoY; International margin decreased 9.1% YoY
Risk Factors
- • Board oversight of cybersecurity delegated to Audit Committee and Compliance and Risk Committee with quarterly meetings and ongoing updates
- • CDIO with 25+ years experience and CISO with 20+ years oversee cybersecurity risk management and incident response
Financial SummaryXBRL
Revenue
$321.3B
Net Income
$1.6B
Gross Margin
3.6%
Operating Margin
0.8%
Net Margin
0.5%
ROE
103.1%
Total Assets
$76.6B
EPS (Diluted)
$7.96
Operating Cash Flow
$3.9B
Source: XBRL data from Cencora FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Cencora
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.